Skip to main content

Table 2 List of analysed variables on drug-related harm reduction interventions and its policy framework

From: The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases

Harm reduction responses in prison Testing, Vaccination, Treatment of infectious diseases in prison Framework and Strategies for harm reduction in prison
Screening of people in prison for drug-related problems upon entry HIV testing available Responsible institution for prison health/prison structure
OST available HIV testing rate (%) among people in prison last year external agencies (incl. NGOs) included in harm reduction service provision
OST coverage 1.—% of prisons where available HIV testing coverage (last year) estimated if rate cannot be calculated Strategy document for drug-related responses in prison available
OST coverage 2. % of people in prison in need receive OST HCV testing available Guidelines/strategy for drug-related responses in prison where
Number of inmates receiving OST HCV testing rate (%) among people in prison last year Guidelines/strategy for harm reduction in prison available
Dominant type of OST medication provided in prisons HCV testing coverage (last year) estimated if rate cannot be calculated Guidelines/strategy for harm reduction in prison where
OST Detoxification available HBV testing available Guidelines/strategy for testing/treatment of infectious diseases in prison available
OST continued for people in prison already in OST before entering prison available HBV testing rate (%) among people in prison last year Guidelines/strategy for testing/treatment of infectious diseases in prison where
OST initiated after entering prison available HBV testing coverage (last year) estimated if rate cannot be calculated Guidelines/strategy for harm reduction measures upon release available
OST initiated before release available TB testing available Guidelines/strategy for harm reduction measures upon release where
NSP available TB testing estimated coverage last year Equivalence of care
NSP coverage 1.—% of prisons where available Vaccination for HBV available Continuity of care
NSP coverage 2.—% of people in prison in need receive NSP HIV post-exposure prophylaxis available  
Distribution of bleach available Antiretroviral therapy for HIV available  
Estimated coverage of bleach distribution: % of prisons where available Antiretroviral therapy for HIV estimated coverage  
Condom provision available Antiviral therapy for HCV available  
Estimated coverage of condom promotion and distribution programmes in prisons, % of prisons where it is provided Antiviral therapy for HCV estimated coverage  
Lubricants provision available Antiviral therapy for HBV available  
Information and education on drug-related health risks (in general) available Antiviral therapy for HBV estimated coverage  
Health education to prevent overdoses during imprisonment available TB treatment available  
Health education (as prevention) on drug-related infectious diseases available TB treatment coverage  
Health education on drug-related infectious diseases coverage: % of people in prison receive it Linkage to HIV care upon release  
Health education (as prevention) on sexually transmitted diseases available Linkage to HCV care upon release  
HIV-related health promotion or behaviour change programmes in prisons coverage   
Information and education on risks of tattooing and piercing available   
Training on safer injecting available   
Harm reduction/addiction service provided to people in prison with drug problem upon release available   
Health education to prevent overdoses upon release available   
Distribution of naloxone upon release available